Rewalk Robotics (RWLK) Receives a Buy from H.C. Wainwright


In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Rewalk Robotics (RWLK), with a price target of $2.50. The company’s shares closed last Tuesday at $1.10.

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 5.0% and a 37.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Trillium Therapeutics.

Rewalk Robotics has an analyst consensus of Moderate Buy, with a price target consensus of $2.50.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ReWalk Robotics Ltd. engages in the design, development and marketing of wearable robotic exoskeletons. Its exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. The firm’s systems include ReWalk Rehabilitation and ReWalk Personal 6.0. The company was founded by Amit Goffer on June 20, 2001 and is headquartered in Yokneam Ilit, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts